AskAt began business operations on February 1, 2013.

AskAt was launched as an independent company from RaQualia Pharma Inc. to focus on developing several strategic programs, including EP4 receptor antagonists, cyclooxygenase (COX-2) inhibitor, and serotonin 5-HT4 partial agonist.  AskAt will also work on new projects.

AskAt will seek to implement innovative structures and collaboration-centric platforms to develop these programs, maximize their value, and then license them to pharmaceutical companies worldwide.  Part of this process optimization will include partnerships with academia, public funding, as well as private financing on a program-specific basis.